The alpha, twice a week
That was 3 min.
Get the best new moments in your inbox every Wednesday and Saturday. It's free.
Check your inbox
We sent a link to your address. Click it to finish signing up. Not there in a minute? Look in spam.
or
How I Invest · 3 min · Nov 16, 2026
Expansion capital can compound more reliably than early venture
Renee Hanna explains why Baylor puts 30% of its private portfolio into expansion capital and how repeatable 3–5x returns can compound.
The episode’s best minutes
Full analysis- 5:50Expansion capital can compound more reliably than early venture3 min
- 13:24A concentrated portfolio helps Baylor focus capital and timePro pick 6 min
- 49:31Later-stage venture can offer attractive risk-adjusted returns3 min
- 5 more moments in the full episode
“They're getting access to these companies where there's 5,000,000 in ARR, scaling at north of 50% per annum”
Takeaways
- Baylor allocates about 30% to expansion capital, versus 2% in the benchmark.
- Some managers target companies with $5 million ARR and over 50% growth.
- A repeatable 3x every five years can compound to 27x in 15 years.
About this segment
Renee Hanna explains why Baylor puts 30% of its private portfolio into expansion capital and how repeatable 3–5x returns can compound. The approach targets growing, overlooked companies with lower loss ratios.
Renee Hanna is a Managing Director of Investments at Baylor University.
Oversees Baylor’s private investments across categories and geographies, bringing nearly two decades of endowment experience.

David Weisburd, Host
From “Baylor Endowment on Rethinking Venture Capital, Concentrated Portfolios, and Power of Compounding”, Nov 16, 2026. Watch the full episode
Thanks. We'll look at and fix what's off.
Transcript
From the transcript How I Invest publishes with the episode.
- 6:03
Talk to me about that strategy. So reminder, we're Baylor University. We're sitting in Waco, Texas. And so part of the reason why we've leaned so heavily into lower middle market, as we were rebuilding the portfolio effectively from scratch beginning in 2014, didn't we have the benefit of having legacy exposure to early stage names. We didn't have Sequoia. We didn't have Benchmark. A lot of those positions have grown organically to be very large allocations within certain university endowments.
- 6:31
Because we didn't have that luxury, we necessarily had to go down a different path of trying to create, upside and capture growth exposure in the portfolio in a different way. And one of the areas that we sought to exploit was effectively this line of expansion capital. And if you look at the Burgess benchmark, it comprises roughly 2% of the underlying allocation versus the market value of venture, which is closer to 14, and buyouts, which is closer to, like, 45%.
- 7:01
And I think the reason why it's only 2% is because there's a lot of miscategorization that happens across these lines. It's kind of a gray area, which to us was the reason why we wanted to lean in. And so effectively, it's orphaned venture assets, something a venture manager would probably not touch because it's either in the middle of the country or it has a smaller TAM. And so, we've been able to pick up these assets where you're coming in at an enterprise value less than $100,000,000 with multiple paths to exit either through M and A activity or selling to larger private equity sponsors.
- 7:33
This episode is presented by Juniper Square, the operations partner for private markets. I've had over 450 episodes. Think this is the first time an institutional investor has gone after this part of the market. Tell me more about the market, and how do you even size it? Our allocation of expansion capital is closer to 30% relative to the 2% that's in the Burgess benchmark. But even within our venture portfolio, we have groups that have venture at the end of their name, but you look through to the underlying portfolio and it's comprised of eight to 10 companies.
- 8:05
They're getting access to these companies where there's 5,000,000 in ARR, scaling at north of 50% per annum, getting ownership stakes of closer to 30%. It doesn't look and feel like an early stage venture manager. The loss ratios are definitely lower than an early stage manager. But they're very consistently having a repeatable process of getting that three to 5X in three to five years, which to us we're very comfortable with because of the compounding nature of those investments.
- 8:31
If I sign up for an early stage venture manager and I am fortunate enough to get a 15X multiple over the course of a fifteen year period, I'm actually better off if I can sign up with a repeatable expansion capital manager that gives me a 3X consistently every five years. Because at the end of the day, I'm sitting on a 27X multiple. As we were building out the portfolio, we found that we had a lot better access to those names, and that seemed like an opportunity that we could continue to exploit.